R Thiebaut

Summary

Country: France

Publications

  1. ncbi request reprint Determinants of response to first HAART regimen in antiretroviral-naïve patients with an estimated time since HIV seroconversion
    R Thiebaut
    INSERM E0338 Biostatistics, Bordeaux 2 University, Bordeaux, France
    HIV Med 7:1-9. 2006
  2. pmc T-cell activation discriminates subclasses of symptomatic primary humoral immunodeficiency diseases in adults
    Marie Quitterie Picat
    INSERM, ISPED, Centre INSERM U897 Epidemiologie Biostatistique, Bordeaux F 33076, France
    BMC Immunol 15:13. 2014
  3. pmc Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design
    Laura Richert
    Universite Bordeaux, ISPED, Centre INSERM U897 Epidemiologie Biostatistique, Bordeaux, F 33000, France
    Trials 15:68. 2014
  4. pmc Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings
    Alexandra Calmy
    HIV Unit, Geneva University Hospital, Geneva, Switzerland
    BMC Infect Dis 12:147. 2012
  5. pmc A novel approach for biomarker selection and the integration of repeated measures experiments from two assays
    Benoit Liquet
    Univ, Bordeaux, ISPED, Centre INSERM U 897 Epidemiologie Biostatistique, Bordeaux, F 33000, France
    BMC Bioinformatics 13:325. 2012
  6. ncbi request reprint Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression
    Rodolphe Thiebaut
    Institut National de la Sante et de la Recherche Medicale INSERM, Institut de Santé Publique, d Epidémiologie et de Développement ISPED, Centre INSERM U897 Epidemiologie Biostatistique, Paris, France
    Clin Infect Dis 55:1417-25. 2012
  7. pmc Pseudomonas aeruginosa acquisition on an intensive care unit: relationship between antibiotic selective pressure and patients' environment
    Alexandre Boyer
    Service de Reanimation Medicale, Hopital Pellegrin Tripode, Place Amelie Raba Leon, 33076 Bordeaux Cedex, France
    Crit Care 15:R55. 2011
  8. pmc Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapy
    Linda Wittkop
    INSERM, Unit 897, Bordeaux, France
    BMC Med Res Methodol 8:68. 2008
  9. ncbi request reprint Biases in observational studies of the effect of prenatal treatment for congenital toxoplasmosis
    Rodolphe Thiebaut
    INSERM U593, Institut de Santé Publique, d Epidémiologie et de Développement ISPED, université Bordeaux 2 Victor Segalen, Bordeaux, France
    Eur J Obstet Gynecol Reprod Biol 124:3-9. 2006
  10. ncbi request reprint Predictors of hypertension and changes of blood pressure in HIV-infected patients
    Rodolphe Thiebaut
    INSERM E0338 epsilont U593, ISPED, Universite Victor Segalen Bordeaux 2, Bordeaux, France
    Antivir Ther 10:811-23. 2005

Detail Information

Publications65

  1. ncbi request reprint Determinants of response to first HAART regimen in antiretroviral-naïve patients with an estimated time since HIV seroconversion
    R Thiebaut
    INSERM E0338 Biostatistics, Bordeaux 2 University, Bordeaux, France
    HIV Med 7:1-9. 2006
    ..To study the determinants of immunological and virological response to highly active antiretroviral therapy (HAART) in naïve patients, adjusting for time since HIV-1 seroconversion...
  2. pmc T-cell activation discriminates subclasses of symptomatic primary humoral immunodeficiency diseases in adults
    Marie Quitterie Picat
    INSERM, ISPED, Centre INSERM U897 Epidemiologie Biostatistique, Bordeaux F 33076, France
    BMC Immunol 15:13. 2014
    ....
  3. pmc Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design
    Laura Richert
    Universite Bordeaux, ISPED, Centre INSERM U897 Epidemiologie Biostatistique, Bordeaux, F 33000, France
    Trials 15:68. 2014
    ..We propose a randomised multi-arm phase I/II design for early stage development of several vaccine strategies, aiming at rapidly discarding those that are unsafe or non-immunogenic...
  4. pmc Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings
    Alexandra Calmy
    HIV Unit, Geneva University Hospital, Geneva, Switzerland
    BMC Infect Dis 12:147. 2012
    ..We assessed the impact of on-going HIV-RNA replication on CD4 cell count slopes in patients treated with a first-line combination ART...
  5. pmc A novel approach for biomarker selection and the integration of repeated measures experiments from two assays
    Benoit Liquet
    Univ, Bordeaux, ISPED, Centre INSERM U 897 Epidemiologie Biostatistique, Bordeaux, F 33000, France
    BMC Bioinformatics 13:325. 2012
    ..We consider the complex structure of repeated measurements from different assays where different conditions are applied on the same subjects...
  6. ncbi request reprint Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression
    Rodolphe Thiebaut
    Institut National de la Sante et de la Recherche Medicale INSERM, Institut de Santé Publique, d Epidémiologie et de Développement ISPED, Centre INSERM U897 Epidemiologie Biostatistique, Paris, France
    Clin Infect Dis 55:1417-25. 2012
    ..It is not known whether markers of inflammation such as high-sensitivity C-reactive protein (hsCRP), interleukin 6 (IL-6), and soluble CD14 (sCD14) may predict disease progression among HIV-2 patients...
  7. pmc Pseudomonas aeruginosa acquisition on an intensive care unit: relationship between antibiotic selective pressure and patients' environment
    Alexandre Boyer
    Service de Reanimation Medicale, Hopital Pellegrin Tripode, Place Amelie Raba Leon, 33076 Bordeaux Cedex, France
    Crit Care 15:R55. 2011
    ..The purpose of this study was to investigate the relationship among Pseudomonas aeruginosa acquisition on the intensive care unit (ICU), environmental contamination and antibiotic selective pressure against P. aeruginosa...
  8. pmc Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapy
    Linda Wittkop
    INSERM, Unit 897, Bordeaux, France
    BMC Med Res Methodol 8:68. 2008
    ..Without pre-selection each mutation presented in at least one patient is considered with a different weight. We compared these two strategies with the construction of a usual genotypic score...
  9. ncbi request reprint Biases in observational studies of the effect of prenatal treatment for congenital toxoplasmosis
    Rodolphe Thiebaut
    INSERM U593, Institut de Santé Publique, d Epidémiologie et de Développement ISPED, université Bordeaux 2 Victor Segalen, Bordeaux, France
    Eur J Obstet Gynecol Reprod Biol 124:3-9. 2006
    ..Given the limitations of existing observational studies and lack of randomised controlled trials, a systematic review of cohort studies offers the best approach for exploring potential biases...
  10. ncbi request reprint Predictors of hypertension and changes of blood pressure in HIV-infected patients
    Rodolphe Thiebaut
    INSERM E0338 epsilont U593, ISPED, Universite Victor Segalen Bordeaux 2, Bordeaux, France
    Antivir Ther 10:811-23. 2005
    ..We assessed predictors of changes in systolic (SBP) and diastolic (DBP) blood pressure during follow-up and of the development of hypertension in HIV-infected individuals...
  11. doi request reprint Long-term nonprogressors and elite controllers in the ANRS CO5 HIV-2 cohort
    Rodolphe Thiebaut
    INSERM U, Bordeaux Segalen University, ISPED, France
    AIDS 25:865-7. 2011
    ..1% (95% confidence interval 3.9-9.1) and 9.1% (6.3-12.7), respectively. Most LTNPs (81%) were HIV controllers, whereas only 55% of HIV controllers were LTNPs...
  12. pmc When it is better to estimate a slope with only one point
    R Thiebaut
    INSERM U897 Epidemiology and Biostatistics, ISPED, Universite Victor Segalen Bordeaux 2, 146 rue Leo Saignat 33076 Bordeaux Cedex, France
    QJM 101:821-4. 2008
    ..In this short note, we explain why this could lead to imprecise and biased estimates. Furthermore, we discuss a standard statistical method that handles such issues...
  13. ncbi request reprint Immunological markers after long-term treatment interruption in chronically HIV-1 infected patients with CD4 cell count above 400 x 10(6) cells/l
    Rodolphe Thiebaut
    INSERM E0338 and U593, ISPED, Universite Bordeaux 2, Bordeaux Cedex, France
    AIDS 19:53-61. 2005
    ..To analyse immunological markers associated with CD4+ lymphocyte T-cell count (CD4+) evolution during 12-month follow-up after treatment discontinuation...
  14. ncbi request reprint Joint modelling of bivariate longitudinal data with informative dropout and left-censoring, with application to the evolution of CD4+ cell count and HIV RNA viral load in response to treatment of HIV infection
    Rodolphe Thiebaut
    INSERM E0338 Biostatistics, ISPED, Universite Victor Segalen Bordeaux 2, 146 rue Leo Saignat, 33076 Bordeaux Cedex, France
    Stat Med 24:65-82. 2005
    ..We apply the model to data from patients starting antiretroviral treatment in the CASCADE collaboration where all of the three issues needed to be addressed...
  15. ncbi request reprint Mixed models for longitudinal left-censored repeated measures
    Rodolphe Thiebaut
    ISPED, INSERM E0338 Biostatistics, Université Victor Segalen Bordeaux II, 146, rue Leo Saignat 33076, Bordeaux Cedex, France
    Comput Methods Programs Biomed 74:255-60. 2004
    ..We show how to fit these models using SAS Proc NLMIXED and we compare this tool with other programs. Indications and limitations of the programs are discussed and an example in the field of HIV infection is shown...
  16. ncbi request reprint Bivariate linear mixed models using SAS proc MIXED
    Rodolphe Thiebaut
    INSERM Unité 330, ISPED, Université Victor Segalen Bordeaux II, 146, rue Leo Saignat 33076, Cedex, Bordeaux, France
    Comput Methods Programs Biomed 69:249-56. 2002
    ..Limitations of this program are discussed and an example in the field of HIV infection is shown. Despite some limitations, SAS Proc MIXED is a useful tool that may be easily extendable to multivariate response in longitudinal studies...
  17. ncbi request reprint Analysis of undetectable HIV RNA using survival analysis: results must be interpreted carefully
    Rodolphe Thiebaut
    INSERM U593, Institut de Santé Publique d Epidémiologie et de Développement, Bordeaux, France
    HIV Clin Trials 4:417-20. 2003
    ..The potential for loss of information might yield differential misclassification biases and therefore unreliable results. Longitudinal models are better suited to analyze the repeated measures of a continuous outcome such as HIV RNA...
  18. ncbi request reprint Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France
    E K Déti
    Institut National de la Santé et de la Recherche Médicale U897, Bordeaux, F 33076, France
    HIV Med 11:308-17. 2010
    ..The aims of the present study were to estimate the prevalence of renal impairment (RI) among HIV-infected adult patients and to investigate the associated factors...
  19. pmc Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort
    Linda Wittkop
    INSERM, Unit Epidemiology and Biostatistics, Bordeaux, France
    J Antimicrob Chemother 63:1251-5. 2009
    ..We studied viro-immunological response, pharmacokinetic parameters and genotypic test results in an observational cohort of multiple ARV class-experienced patients starting a raltegravir-based regimen...
  20. ncbi request reprint Determinants of smoking cessation attempts among HIV-infected patients results from a hospital-based prospective cohort
    Gaelle Encrenaz
    INSERM, U897, CIC EC7, Bordeaux, F 33076 France
    Curr HIV Res 8:212-7. 2010
    ..Tobacco smoking is a major modifiable risk factor of these emergent conditions and almost half of these patients are regular smokers in resource-rich countries...
  21. ncbi request reprint Trends and determinants of severe morbidity in HIV-infected patients: the ANRS CO3 Aquitaine Cohort, 2000-2004
    F Bonnet
    CHU de Bordeaux, Services de Médecine Interne et Maladies Infectieuses, Bordeaux, France
    HIV Med 8:547-54. 2007
    ..The aim of the study was to characterize the causes, trends and determinants of severe morbidity in a large cohort of HIV-infected patients between 2000 and 2004...
  22. pmc Bacterial pneumonia among HIV-infected patients: decreased risk after tobacco smoking cessation. ANRS CO3 Aquitaine Cohort, 2000-2007
    Antoine Benard
    INSERM, U897, CIC EC7, Bordeaux, France
    PLoS ONE 5:e8896. 2010
    ..Our objective was to estimate the effect of tobacco smoking withdrawal on the risk of bacterial pneumonia among HIV-infected individuals...
  23. ncbi request reprint A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997-1999
    F Bonnet
    Fédération de médecine interne, Maladies Infectieuses et Pathologies Tropicales, Hôpital Saint André, Centre Hospitalier Universitaire de Bordeaux, Universite Victor Segalen, Bordeaux, France
    Clin Infect Dis 35:1231-7. 2002
    ..Coinfection with HCV or HBV increased the risk of hepatotoxicity, which lead to the cautious use of nevirapine for such patients...
  24. ncbi request reprint Incidence and risk factors of severe hypertriglyceridaemia in the era of highly active antiretroviral therapy: the Aquitaine Cohort, France, 1996-99
    R Thiebaut
    Unité INSERM 330, Institut de Santé Publique, d Epidémiologie et de Développement ISPED, Universite Victor Segalen Bordeaux 2, Bordeaux, France
    HIV Med 2:84-8. 2001
    ..To estimate the incidence of serum hypertriglyceridaemia > 6 mm/L (HTG) and identify associated factors in the era of highly active antiretroviral therapy (HAART)...
  25. ncbi request reprint Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002
    F Bonnet
    Department of Internal Medicine and Infectious Diseases, Saint Andre Hospital, Bordeaux University Hospital, Bordeaux, France
    HIV Med 6:198-205. 2005
    ..To determine the factors associated with clinical progression (AIDS events and death) in antiretroviral-naive patients who have begun highly active antiretroviral therapy (HAART)...
  26. doi request reprint Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy
    Olivia Peuchant
    Virology Laboratory, Bordeaux University Hospital, Bordeaux, France
    AIDS 22:1417-23. 2008
    ..We investigated the clinical relevance of the detection of majority and minority-resistant variants in an observational study in antiretroviral therapy naive, recently infected patients...
  27. ncbi request reprint Weight loss and body mass index as predictors of HIV disease progression to AIDS in adults. Aquitaine cohort, France, 1985-1997
    E Malvy
    Unité INSERM 330, Universite Victor Segalen Bordeaux 2, Hĵpital Saint André, Centre Hospitalier Universitaire de Bordeaux, France
    J Am Coll Nutr 20:609-15. 2001
    ..To assess the performance of weight related nutritional markers (reported involuntary weight loss greater than 10%, measured weight loss and body mass index-BMI-) in predicting HIV disease progression...
  28. ncbi request reprint [Epidemiology of discordant virologic and immunologic responses in HIV-1 infected patients]
    R Thiebaut
    INSERM E0338 et INSERM U593, ISPED, Universite Bordeaux 2, Bordeaux, France
    Med Mal Infect 35:S31-2. 2005
  29. pmc Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients
    Isabelle Pellegrin
    Department of Virology, INSERM U593, Bordeaux University Hospital, France
    Antimicrob Agents Chemother 51:1473-80. 2007
    ..Specific mutations, PK and GIQ, provide relevant information for monitoring fosamprenavir-ritonavir-based HAART...
  30. ncbi request reprint Time-updated CD4+ T lymphocyte count and HIV RNA as major markers of disease progression in naive HIV-1-infected patients treated with a highly active antiretroviral therapy: the Aquitaine cohort, 1996-2001
    Rodolphe Thiebaut
    Institut National de la Santé et de la Recherche Médicale Unité 330, Institut de Santé Publique, d Épidémiologie et de Développement, Universite Victor Segalen, Bordeaux, France
    J Acquir Immune Defic Syndr 33:380-6. 2003
    ..Clinical decisions and interpretation of clinical trial results must weigh the signification of each of these 2 biomarkers...
  31. ncbi request reprint Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/microl? Impact on immunovirological parameters
    Isabelle Pellegrin
    Department of Virology and Immunology, Bordeaux University Hospital, Bordeaux, France
    J Med Virol 77:164-72. 2005
    ..HIV1 DNA genotyping helps monitor patients with undetectable HIV RNA at M0...
  32. ncbi request reprint Maximum likelihood estimation in dynamical models of HIV
    J Guedj
    INSERM, U875 Biostatistique, Bordeaux, F 33076, France
    Biometrics 63:1198-206. 2007
    ..We apply this approach to the analysis of a clinical trial of antiretroviral therapy (ALBI ANRS 070) and we show that the whole algorithm works well in a simulation study...
  33. ncbi request reprint [Analysis of left-censored quantitative outcome: example of procalcitonin level]
    J Asselineau
    Unité de Soutien Méthodologique à la Recherche Clinique et Epidémiologique, CHU de Bordeaux, ISPED, 33076 Bordeaux, France
    Rev Epidemiol Sante Publique 55:213-20. 2007
    ..Analysis of such data requires appropriate statistical techniques. In this study, we aimed at comparing various methods used to deal with left-censored outcome in regression analysis...
  34. ncbi request reprint Bivariate longitudinal model for the analysis of the evolution of HIV RNA and CD4 cell count in HIV infection taking into account left censoring of HIV RNA measures
    Rodolphe Thiebaut
    INSERM EMI 0338, Institut de Santé Publique d Épidémiologie et de Développement ISPED, Universite Victor Segalen Bordeaux 2, Bordeaux, France
    J Biopharm Stat 13:271-82. 2003
    ..Despite some limitations (distribution assumption, ignorance of missingness process), such a model appeared to be very useful to correctly describe the current evolution of important biomarkers in HIV infection...
  35. doi request reprint Score tests for exploring complex models: application to HIV dynamics models
    Julia Drylewicz
    INSERM U897, Epidemiology and Biostatistics Research Center, Bordeaux, France
    Biom J 52:10-21. 2010
    ..We study type I errors and the statistical powers of this score test statistics and we apply the score test approach to a real data set of HIV-infected patients...
  36. ncbi request reprint Factors associated with the occurrence of AIDS-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: Aquitaine Cohort, France
    Fabrice Bonnet
    Service de Medecine Interne et Maladies Infectieuses, Hôpital Saint André, Bordeaux, France
    Clin Infect Dis 42:411-7. 2006
    ....
  37. ncbi request reprint Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study)
    Isabelle Pellegrin
    Department of Virology, Bordeaux University Hospital, Bordeaux, France
    Antivir Ther 13:271-9. 2008
    ....
  38. doi request reprint Validation and comparison of simple noninvasive indexes for predicting liver fibrosis in HIV-HCV-coinfected patients: ANRS CO3 Aquitaine cohort
    Marc Arthur Loko
    INSERM, U593, Bordeaux, France
    Am J Gastroenterol 103:1973-80. 2008
    ..Although an increasing number of noninvasive fibrosis markers are available in HCV-monoinfected patients, data on the performance of these tests in HIV-HCV-coinfected patients are lacking...
  39. ncbi request reprint CD4+ T-lymphocytes natural decrease in HAART-naïve HIV-infected adults in Abidjan
    J Duvignac
    INSERM U593, Bordeaux, France
    HIV Clin Trials 9:26-35. 2008
    ..To study the CD4 natural decrease and its determinants in sub-Saharan African HIV-infected adults...
  40. ncbi request reprint Practical identifiability of HIV dynamics models
    J Guedj
    INSERM, U875 Biostatistique, Bordeaux, 33076, France
    Bull Math Biol 69:2493-513. 2007
    ....
  41. ncbi request reprint Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort
    Eric Balestre
    INSERM U593, Universite Victor Segalen, Bordeaux, France
    J Clin Virol 36:95-9. 2006
    ..We wished to investigate the virological response to these regimens in a large cohort of antiretroviral (ARV)-treated patients...
  42. doi request reprint Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field
    Linda Wittkop
    INSERM U897, Research Centre for Epidemiology and Biostatistics, Bordeaux, France
    Clin Trials 7:19-35. 2010
    ..g. rapid virological suppression) or the licensing requirements of official drug approval organizations (e.g. time to loss of virological response [TLOVR])...
  43. pmc Estimation of dynamical model parameters taking into account undetectable marker values
    Rodolphe Thiebaut
    INSERM E0338 Biostatistics, Bordeaux 2 University, Bordeaux, France
    BMC Med Res Methodol 6:38. 2006
    ..A method is proposed to take into account left-censored values for estimating parameters of non linear mixed models and its impact is demonstrated through a simulation study and an actual clinical trial of anti-HCV drugs...
  44. doi request reprint Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells
    Sandrine Reigadas
    Laboratory of Virology, EA2968, University of Bordeaux 2, Bordeaux, France
    J Antimicrob Chemother 65:434-7. 2010
    ..Our aim was to analyse the evolution of HIV-1 2-long terminal repeat (2-LTR) circular DNA in vitro and ex vivo in the presence of raltegravir...
  45. ncbi request reprint HIV type-1 transmission dynamics in recent seroconverters: relationship with transmission of drug resistance and viral diversity
    Patricia Recordon-Pinson
    CHU de Bordeaux, Laboratoire de Virologie, and Université Victor Segalen Bordeaux 2, Bordeaux, France
    Antivir Ther 14:551-6. 2009
    ..We investigated the relationship between the dynamics of HIV-1 transmission within recently infected patients, the HIV-1 variability and the transmission of antiretroviral drug resistance...
  46. ncbi request reprint Options for clinical trials of pre and post-natal treatments for congenital toxoplasmosis
    Genevieve Chene
    INSERM U897 Epidemiology and Biostatistics, Bordeaux School of Public Health, Bordeaux University, Bordeaux, France
    Mem Inst Oswaldo Cruz 104:299-304. 2009
    ....
  47. ncbi request reprint Comparison of early CD4 T-cell count in HIV-1 seroconverters in Côte d'Ivoire and France: the ANRS PRIMO-CI and SEROCO cohorts
    Charlotte Lewden
    INSERM, U897, Bordeaux, France
    J Acquir Immune Defic Syndr 53:260-5. 2010
    ..We compared CD4+ decline among untreated HIV-1-infected seroconverters living in Côte d'Ivoire (CI) and in France...
  48. pmc Effectiveness of disease-management programs for improving diabetes care: a meta-analysis
    Clément Pimouguet
    Institut National de la Sante et de la Recherche Medicale, Bordeaux, France
    CMAJ 183:E115-27. 2011
    ....
  49. doi request reprint Dynamical models of biomarkers and clinical progression for personalized medicine: the HIV context
    M Prague
    University of Bordeaux, ISPED Epidémiologie Biostatistique, F 33000 Bordeaux, France INSERM, ISPED, centre Inserm U897, F 33000 Bordeaux, France
    Adv Drug Deliv Rev 65:954-65. 2013
    ..Finally, the control theory and the use of intrinsic properties of mechanistic models make them very relevant for dynamic treatment adaptation. Their implementation would nevertheless require their evaluation through clinical trials. ..
  50. ncbi request reprint [Epidemiology of atherosclerotic cardiovascular risk in HIV-1 infected patients]
    R Thiebaut
    Institut de Santé Publique, d Épidémiologie et de Développement, INSERM U593, Universite Victor Segalen, Bordeaux 33
    Presse Med 32:1419-26. 2003
    ..The main risk factors seem to be classical risk factors such as smoking habits, age and dyslipidemia that are partly due themselves to highly active antiretroviral treatments..
  51. ncbi request reprint [Joint modeling of quantitative longitudinal data and censored survival time]
    H Jacqmin-Gadda
    INSERM E 0338, Université Victor Segalen Bordeaux II, Case 11, 146, rue Leo Saignat, 33076 Bordeaux Cedex, France
    Rev Epidemiol Sante Publique 52:502-10. 2004
    ..Such models allow, for example, to perform survival analysis when a time-dependent explanatory variable is measured intermittently, or to study the evolution of a quantitative marker conditionally to an event...
  52. ncbi request reprint Change in atherosclerosis progression in HIV-infected patients: ANRS Aquitaine Cohort, 1999-2004
    Rodolphe Thiebaut
    INSERM EMI 0338, ISPED, Universite Victor Segalen Bordeaux 2, 33076 Bordeaux, France
    AIDS 19:729-31. 2005
    ..The progression of atherosclerosis in HIV-infected patients can be controlled. The impact of individual measures to reduce the cardiovascular risk should be evaluated further...
  53. ncbi request reprint Pravastatin in HIV-infected patients treated with protease inhibitors: a placebo-controlled randomized study
    Fabrice Bonnet
    Service de Medecine Interne et Maladies Infectieuses, Hôpital Saint André, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
    HIV Clin Trials 8:53-60. 2007
    ..5 mmol/L...
  54. pmc Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection
    Estibaliz Lazaro
    Department of Internal Medicine and Infectious Diseases, Bordeaux University Hospital, Bordeaux, France
    Antivir Ther 11:343-50. 2006
    ..To compare changes in CD4+, CD8+ and total lymphocyte counts after initiation of highly active antiretroviral therapy (HAART) between HIV-infected patients with and without a recent history of Mycobacterium avium complex (MAC) infection...
  55. ncbi request reprint Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data
    Rodolphe Thiebaut
    INSERM, Bordeaux, France
    Lancet 369:115-22. 2007
    ..Despite three decades of prenatal screening for congenital toxoplasmosis in some European countries, uncertainty remains about the effectiveness of prenatal treatment...
  56. ncbi request reprint Evidence that an identical T cell clone in skin and peripheral blood lymphocytes is an independent prognostic factor in primary cutaneous T cell lymphomas
    M Beylot-Barry
    Equipe Histologie et Pathologie Moléculaire 12406, Universite Victor Segalen Bordeaux 2, France
    J Invest Dermatol 117:920-6. 2001
    ..A fully prospective study, with simultaneous therapeutic trials, needs to be done to confirm our findings and to include treatment variables in the statistical analysis...
  57. ncbi request reprint Reduced bone mineral density in HIV-infected patients: prevalence and associated factors
    Charles Cazanave
    Fédération de maladies infectieuses et tropicales, Hopital Pellegrin, Place A, Raba Léon, 33076 Bordeaux Cedex, France
    AIDS 22:395-402. 2008
    ..There is a high prevalence of bone demineralization among HIV-infected patients but mechanisms of alteration of bone turnover are still unclear and it is thought to be multifactorial...
  58. pmc Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy
    Benoit Marin
    INSERM, U897, Bordeaux, France
    AIDS 23:1743-53. 2009
    ..To assess whether immunodeficiency is associated with the most frequent non-AIDS-defining causes of death in the era of combination antiretroviral therapy (cART)...
  59. pmc Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study
    Y Levy
    INSERM, U955, France
    Clin Infect Dis 55:291-300. 2012
    ..The immune deficiency of human immunodeficiency virus (HIV) infection is not fully corrected with ARV therapy. Interleukin-7 (IL-7) can boost CD4 T-cell counts, but optimal dosing and mechanisms of cellular increases need to be defined...
  60. doi request reprint TNFSF15 polymorphisms are associated with susceptibility to inflammatory bowel disease in a new European cohort
    R Thiebaut
    INSERM, U843, Hopital Robert Debre, Universite Paris Diderot, Paris, France
    Am J Gastroenterol 104:384-91. 2009
    ..This replication study was designed in order to confirm and further validate the role of TNFSF15 in IBD...
  61. ncbi request reprint Prevalence and occupational covariates of mood, anxiety disorders, and alcohol dependence in a French ancillary staff population
    R Thiebaut
    Département d information médicale, Universite Victor Segalen Bordeaux 2, 146, rue Leo Saignat, CH Charles Perrens France
    Eur Psychiatry 14:210-6. 1999
    ....
  62. pmc Prediction of cytomegalovirus (CMV) plasma load from evaluation of CMV whole-blood load in samples from renal transplant recipients
    Isabelle Garrigue
    Universite Victor Segalen Bordeaux 2, Laboratoire de Virologie EA2968, 146 rue Leo Saignat, 33 076 Bordeaux Cedex, France
    J Clin Microbiol 46:493-8. 2008
    ..WB seems to be an appropriate candidate for routine CMV monitoring of transplant recipients by using a single assay...
  63. ncbi request reprint Behavioral audiometry: validity of audiometric measurements obtained using the "Delaroche protocol" in babies aged 4--18 months suffering from bilateral sensorineural hearing loss
    Monique Delaroche
    Pediatric Audiology Unit, CHU Pellegrin, Bordeaux, France
    Int J Pediatr Otorhinolaryngol 70:993-1002. 2006
    ....
  64. ncbi request reprint Effectiveness of health education on Toxoplasma-related knowledge, behaviour, and risk of seroconversion in pregnancy
    ERICA L GOLLUB
    INSERM, U593, Bordeaux, Universite Victor Segalen Bordeaux 2, Institut de Santé Publique, d Épidémiologie et de Développement, Bordeaux, F 33076 Bordeaux cedex, France
    Eur J Obstet Gynecol Reprod Biol 136:137-45. 2008
    ..There is suggestive evidence that health education approaches may help reduce risk of congenital toxoplasmosis but this problem requires further study using more rigorous research design and methodology...
  65. ncbi request reprint Decrease in circulating dendritic cells predicts fatal outcome in septic shock
    Olivier Guisset
    Département de Réanimation Médicale et Urgences, Hôpital St André, CHU de Bordeaux, Bordeaux, France
    Intensive Care Med 33:148-52. 2007
    ..Experimental models of septic shock in mouse previously noted a decrease in dendritic cell numbers. The aim of the study was to find a rapid reproducible biological test for an assessment of disease severity...